What is Evolus Inc (EOLS) stock price today?

Evolus Inc (EOLS) currently trades at $5.18 per share. The stock has a market capitalization of $344.82M and a P/E ratio of —x.

Is EOLS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Evolus Inc has a Smart Value Score of 32/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Evolus Inc's revenue and earnings?

Evolus Inc has trailing twelve-month (TTM) revenue of $297.18M with profit margins of -17.40%. Earnings per share (EPS) is $-0.80.

Is EOLS stock overvalued or undervalued?

Based on our DCF model, Evolus Inc's intrinsic value is $21.15, representing a margin of safety of 79.67%. The stock currently trades at a P/E of —x.

EOLS

Evolus Inc

NASDAQ: EOLS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$5.18

-1.71% today

Updated 2026-04-29

Market cap

$344.82M

P/E ratio

—

P/S ratio

1.16x

EPS (TTM)

$-0.80

Dividend yield

—

52W range

$4 – $12

Volume

1.1M

Market cap

$344.82M

P/E ratio

—

P/S ratio

1.16x

EPS (TTM)

$-0.80

Dividend yield

—

52W range

$4 – $12

Volume

1.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.7

Growth

5.0

Quality

C+

2.0

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$14.67

+183.20%

12-Month target

—

Intrinsic (DCF)

$21.15

Margin of safety

+79.67%

1 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Free cash flow $11.35M — positive

+ Revenue growth 14.40% QoQ

+ 79.67% below intrinsic value

Risks

- Thin margins at -17.40%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$148.62M	$202.09M	$266.27M	$297.18M	$297.18M
Net income	$-74.41M	$-61.69M	$-50.42M	$-51.64M	$130000.00
EPS	—	—	—	—	$-0.80
Free cash flow	$-87.85M	$-35.63M	$-19.47M	$-45.71M	$11.35M
Profit margin	-50.07%	-30.52%	-18.94%	-17.38%	-17.40%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-20	MOATAZEDI, DAVID	Sale	13,669	$4.75
2026-03-20	AVELAR, RUI	Sale	3,119	$4.75
2026-03-17	MOATAZEDI, DAVID	Sale	116,720	$4.89

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
EOLS	$344.82M	32	6.7	2.0	6.7	5.0	+79.67%	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Evolus Inc trades at $5.18. Our Smart Value Score of 32/100 indicates the stock is weak. TTM revenue stands at $297.18M. with profit margins at -17.40%. Our DCF model estimates intrinsic value at $21.15.

Frequently asked questions

What is Evolus Inc's stock price?

Evolus Inc (EOLS) trades at $5.18.

Is Evolus Inc overvalued?

Smart Value Score 32/100 (Grade F, Strong Sell). DCF value $21.15.

What is the price target of Evolus Inc (EOLS)?

The analyst target price is $14.67, representing +183.2% upside from the current price of $5.18.

What is the intrinsic value of Evolus Inc (EOLS)?

Based on our DCF model, intrinsic value is $21.15, a +79.7% margin of safety versus $5.18.

What is Evolus Inc's revenue?

TTM revenue is $297.18M.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1.16x

ROE-18,730.00%

Beta1.00

50D MA$4.62

200D MA$6.25

Shares out0.07B

Float0.05B

Short ratio—

Avg volume1.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

EOLS vs LLY →EOLS vs JNJ →EOLS vs ABBV →Stock screener →